A Phase 1 interventional study of DE-117 in Healthy Male Adults, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-29.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Basic science
The purposes of this study are to evaluate the safety and plasma pharmacokinetics of DE-117 ophthalmic solution (one drop once daily for 7 days) in healthy male adults.
Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: DE-117
Area under concentration-time curve (AUC)
Time frame: 7 days
Maximum plasma concentration (Cmax)
Time frame: 7 days
Time to maximum plasma concentration (Tmax)
Time frame: 7 days
Elimination half-life (T1/2)
Time frame: 7 days
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Pharmaceutical Co., Ltd.